Targets › CETP
3 programs from 3 companies in 9 trials: 6 Phase 3, 3 Phase 2; Cardiovascular, Neurology, Metabolic and endocrine; next expected readout Nov 2026.
Involved in the transfer of neutral lipids, including cholesteryl ester and triglyceride, among lipoprotein particles. Allows the net movement of cholesteryl ester from high density lipoproteins/HDL to triglyceride-rich very low density lipoproteins/VLDL, and the equimolar transport of triglyceride from VLDL to HDL. Regulates the reverse cholesterol transport, by which excess cholesterol is removed from peripheral…. (UniProt, P11597)
Open in Phaseline: the race on CETP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| NewAmsterdam Pharma | obicetrapib Cholesteryl ester transfer protein inhibitor | CETP | Phase 3 | Atherosclerotic Cardiovascular Disease; Lipidemia; Dyslipidemias; Antioxidant Absorption … | Nov 2026 |
| DalCor Pharmaceuticals | Dalcetrapib Cholesteryl ester transfer protein inhibitor | CETP | Phase 3 | Acute Coronary Syndrome | Aug 2027 |
| University of Oxford | Anacetrapib Cholesteryl ester transfer protein inhibitor | CETP | Phase 3 | Atherosclerotic Cardiovascular Disease | Jan 2037 |
Lipidemia (3) Atherosclerotic Cardiovascular Disease (2) Dyslipidemias (1) Antioxidant Absorption (1) Preclinical Alzheimer's Disease (1) Acute Coronary Syndrome (1)
small molecule (3)
University of Oxford (1) NewAmsterdam Pharma (1) DalCor Pharmaceuticals (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.